Loading...
XNASPALI
Market cap4mUSD
Dec 26, Last price  
1.77USD
1D
3.51%
1Q
-47.16%
IPO
-99.98%
Name

Palisade Bio Inc

Chart & Performance

D1W1MN
XNAS:PALI chart
P/E
—
P/S
19.58
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
90.42%
Rev. gr., 5y
-0.78%
Revenues
250k
265,759306,05700733,438390,625407,708110,00018,83310,41716,246260,000260,00015,39413,52000250,000
Net income
-12m
L-3.90%
-3,147,487-6,174,121-11,830,798-10,364,363-18,387,300-12,518,527-10,121,517-19,831,862-22,628,744-20,903,901-21,074,611-15,665,983-4,924,617-8,351,651-10,570,000-27,271,000-12,799,000-12,300,000
CFO
-11m
L-16.67%
-3,334,927-4,001,368-6,860,039-5,144,820-9,981,244-8,096,696-8,477,700-10,591,617-11,706,688-18,931,666-15,616,108-13,416,162-7,692,419-7,255,680-4,768,000-14,773,000-13,360,000-11,133,000
Earnings
Mar 25, 2025

Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
URL
https://palisadebio.com/
IPO date
Dec 20, 2006
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
250
 
Cost of revenue
13,095
15,478
42,022
Unusual Expense (Income)
NOPBT
(12,845)
(15,478)
(42,022)
NOPBT Margin
Operating Taxes
(1,461)
655
Tax Rate
NOPAT
(12,845)
(14,017)
(42,677)
Net income
(12,300)
-3.90%
(12,799)
-53.07%
(27,271)
158.00%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,419
14,401
24,943
BB yield
-233.39%
-314.60%
-205.25%
Debt
Debt current
279
193
199
Long-term debt
301
527
112
Deferred revenue
Other long-term liabilities
63
61
2,651
Net debt
(11,852)
(11,689)
(10,210)
Cash flow
Cash from operating activities
(11,133)
(13,360)
(14,773)
CAPEX
(4)
(10)
Cash from investing activities
(4)
(10)
(54)
Cash from financing activities
11,186
15,258
24,609
FCF
(12,743)
(14,215)
(48,480)
Balance
Cash
12,432
12,383
10,495
Long term investments
26
26
Excess cash
12,420
12,409
10,521
Stockholders' equity
(121,411)
(109,158)
(94,497)
Invested Capital
133,156
122,102
104,712
ROIC
ROCE
EV
Common stock shares outstanding
456
59
12
Price
8.85
-88.65%
78.00
-92.00%
975.00
 
Market cap
4,036
-11.84%
4,578
-62.33%
12,152
 
EV
(7,814)
(7,109)
1,944
EBITDA
(12,841)
(15,475)
(42,020)
EV/EBITDA
0.61
0.46
Interest
15
13
2,398
Interest/NOPBT